The IDH2 gene helps cells make energy and keep a healthy chemical balance inside mitochondria, the parts of cells that act like power centers. If it does not work normally, cells can build up unusual chemicals that disrupt how they grow and function. Some IDH2 variants are acquired during life and are linked to certain cancers, especially acute myeloid leukemia and some bile duct cancers. Rare inherited variants can also affect brain development and movement.
What is a gene?
A gene is a stretch of DNA that holds instructions your cells can use to make molecules or manage processes in the body. Some genes carry the directions for making proteins, the working parts of cells. Other genes mostly help decide when certain processes happen, where they happen, and how strongly they run. Together, genes affect how the body develops and works, and they can help shape how you respond to food, stress, or medications. To go into this topic in more detail, you can find more in the LearnHub.
Overview
IDH2Gene function
What if the gene works
The IDH2 gene helps mitochondria, your cells’ energy centers, process nutrients. Its protein supports normal cell chemistry and makes NADPH, a molecule that helps protect cells from everyday damage.
Risk
What if the gene does not work
Pathogenic variants in the IDH2 gene are linked to some blood cancers and, rarely, a developmental condition with delayed development, low muscle tone, seizures, or heart involvement. Milder and severe variants can influence which features appear and how strongly.
Treatment
What does that mean for your treatment
A pathogenic variant in the IDH2 gene can make some people with acute myeloid leukemia eligible for enasidenib, a targeted medicine used in current guidelines. This treatment choice depends on having a susceptible IDH2 variant and is mainly used in specific settings, including relapsed or refractory disease.
Conditions associated with IDH2
Gene function
What if the gene works
In your cells, the IDH2 gene supports the steady work mitochondria do every day. It helps cells get useful energy from nutrients while also supplying chemical support for antioxidant protection. Understanding how the IDH2 gene works helps explain how cells keep energy production and internal balance on track.
In mitochondria, the IDH2 gene helps carry out a key step in turning nutrients into usable cell energy. Its protein changes one small fuel related molecule into another that cells use in routine energy making and cell chemistry.
The IDH2 gene also helps make NADPH, a helper molecule that supplies the cell's antioxidant systems. This support helps mitochondria handle normal oxidative stress, or chemical wear and tear, from everyday energy production.
By supplying alpha-ketoglutarate, a small molecule used across many pathways, the IDH2 gene supports how cells process amino acids and other nutrients. This helps keep routine metabolism steady from one moment to the next.
What is a variant?
A genetic variant is a small difference in the DNA sequence of a gene. These changes are common and help shape normal human diversity, including differences in appearance, metabolism, or how the body responds to environmental influences. Many variants do not have any noticeable effect and are simply part of natural genetic variation. In some cases, though, a variant can change how a gene works more substantially and may contribute to or cause a genetic condition.
Genetic variants
What if the gene does not work
Most disease linked variants in the IDH2 gene reshape the enzyme and change enzyme activity, causing excess 2-hydroxyglutarate to build up. This helps explain how IDH2 gene variants change enzyme activity in cells, because the extra chemical can disrupt gene control and interfere with normal cell maturation. Some variants have milder effects, while others drive stronger abnormal activity, which may influence how early or how noticeably IDH2 related features appear.
How variants are linked to conditions
Pathogenic variants in the IDH2 gene can cause D-2-hydroxyglutaric aciduria type 2, a rare inherited condition that may affect development and the nervous system. Separate acquired variants in the IDH2 gene are linked to some cancers, especially acute myeloid leukemia, and are also found in certain cartilage and bile duct tumors. This is how IDH2 gene variants are linked to conditions: some confirm a rare genetic diagnosis, while others are changes present only in tumor cells.
A variant is not necessarily a diagnosis
Genetic variants are common across the general population and are a normal feature of human biology. Most do not have a direct effect on health and simply contribute to natural human diversity. For many genes, having a variant linked to a condition points to a possible association rather than a definitive diagnosis, especially when several genes and environmental factors are involved. Still, in some situations, a single well-characterized variant in a specific gene can be enough to confirm a diagnosis.
Are there things that can increase or change my risk?
There is not yet broadly confirmed evidence on specific factors that clearly increase or reduce health risk specifically related to the IDH2 gene. For many living with an IDH2 change, risk depends most on the exact change itself and whether it is inherited or found only in tumor cells, so personal guidance from a doctor or genetic counselor can help put results in context.
Inheritance of IDH2 variants
For the inherited condition linked to the IDH2 gene, the IDH2 inheritance pattern is autosomal dominant. This means a child can inherit the gene change from either parent, and each child of a parent who carries it has a 50% chance of inheriting the same variant. Some people with an IDH2-related condition have a new, de novo variant, which means it was not inherited from either parent.
What does my IDH2 result mean for my family?
For the rare inherited condition linked to the IDH2 gene, the pattern is usually dominant, so a parent, child, brother, or sister could also carry the same change. Some cases happen for the first time in one person, so an affected child does not always inherit it from a parent. If your IDH2 result came from tumor testing, it is often an acquired change in the cancer itself and usually does not have the same meaning for relatives.
Genetic information
Genetic testing
How you find out about variants
To find IDH2 variants, doctors use IDH2 genetic testing on a blood, saliva, or bone marrow sample, depending on why testing is needed. The lab reads the DNA code of the IDH2 gene to look for changes linked to inherited conditions or present only in cancer cells. Results show whether an IDH2 variant was found and what it may mean.
When should I consider getting a genetic test?
Testing for IDH2 is mainly considered after a diagnosis of acute myeloid leukemia or certain other cancers, because finding a change in this gene can help classify the cancer and guide treatment. In rare cases, testing may also be considered in a child with developmental delay and other signs of a rare condition linked to IDH2.
A genetic result is only one part of your health story
A genetic result can be informative, but how much it reveals depends on the condition and the kind of variant involved. Over time, many factors, including lifestyle, environment, age, and medical history, also shape how the body functions. For some conditions, especially those influenced by many genes, genetic information provides context rather than certainty and is best understood together with other parts of care. In other situations, a genetic result may give a clear answer. In areas such as medication response, genetic results can also help put individual experiences into context.
Pharmacogenetics
How variants shape your response to medicine
Genetic variation can affect how your body handles certain medicines, including how quickly a drug is broken down or how strongly your body responds to it. This helps explain why the same treatment may work well for one person but cause more side effects or less benefit in another. These differences are common and are one part of the reason medication response can vary alongside age, other health conditions, and other medicines.
What is Pharmacogenetics?
Pharmacogenetics examines how differences in genes can affect the way people respond to medicines. It focuses on patterns between genes and drugs to help explain why the same treatment may work differently from one person to another. For many medications, genes can influence both how strongly a drug works and how the body handles it. This information can support treatment decisions that are better informed and more individualized. More detail on this topic is available in the LearnHub.
Drugs influenced by the IDH2 gene
When should I seek medical advice?
There is not yet a broadly confirmed role for this gene in routine medication response, so general questions about medicines or side effects are best discussed with your doctor. IDH2 is different in cancer care: changes found in tumor cells, especially in some blood cancers, can sometimes help guide treatment choices with a cancer specialist.
History
The IDH2 gene came to wider attention in the late 2000s, when researchers found recurring variants in brain tumors and later in leukemia. This was an important shift because cancer genes were usually thought to drive disease mainly through growth signals, not by changing cell chemistry in such a direct way. From these first observations, research expanded steadily. Scientists then showed that altered IDH2 could lead to a buildup of an unusual chemical signal inside cells, helping reshape ideas about how some cancers begin and behave. That discovery opened a new chapter in cancer research and supported the development of targeted medicines. Today, the IDH2 gene is best known as part of that broader story in precision cancer care.